hims stock has broken above $30 ahead of an upcoming fda peptide review, with analysts looking for the next growth catalyst. However, there are conflicting reports about the stock's recent performance, with some outlets indicating a 3-day slide and others noting a snap in a losing streak. The stock's movement is being closely watched, with some considering whether it is a good time to buy.